This is a preview. Log in through your library . Abstract Ubiquitin-conjugating enzymes (E2s) collaborate with the ubiquitin-activating enzyme (E1) and ubiquitin ligases (E3s) to attach ubiquitin to ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated allosteric binders of angiotensin-converting enzyme 2 (ACE2) that significantly inhibit severe acute respiratory ...

Sir2, an enzyme belonging to sirtuins, has been effectively involved in the deacetylation of proteins. A tandem allosteric effect of reactant and product is responsible for the efficient deacetylation ...

Scientists have created a new way of screening compounds that is more sensitive than existing methods, opening up the possibility of finding new drugs for many diseases. Scientists have created a new ...

Researchers present novel therapeutics that rejuvenate a previously undruggable mitochondrial regulator of aging through a new mode of enzyme activation. Leveraging a newly identified biophysical ...

Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

Sir2, an enzyme belonging to sirtuins, has been shown to be involved in the deacetylation of proteins. Researchers from the Institute of Science Tokyo reveal that a tandem allosteric effect of ...

In this Innovation Spotlight, Gene Mack, the chief executive officer of Gain Therapeutics, discusses the company’s Magellan™ platform, which uss machine learning and structural modeling to identify ...

Professor Nicolas Doucet and his team at Institut national de la recherche scientifique (INRS) made a major breakthrough earlier this year in the field of evolutionary conservation of molecular ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 74, No. 7 (Jul., 1977), pp. 2766-2770 (5 pages) Escherichia coli glutamine synthetase and glycogen phosphorylase ...